Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
After several discontinuations, a new ADC enters the clinic.
Median PFS appears to back earlier response rate promise.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Solstice Oncology acquires porustobart from Harbour Biomed.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
